## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the βgold standardβ against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor
Levodopa in the treatment of Parkinson's disease: Current controversies
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 27 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The original article to which this Erratum refers was published in the September, 2004 issue of Movement Disorders (2004) 19 (9) 997β1005.
π SIMILAR VOLUMES
## Abstract Companion letters have been published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.
## Abstract The original articles to which this Letter refers have published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Rei
## Abstract Companion letters have been published in __Movement__ Disorders: Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Reichmann, and Riederer and Reply: Levodopa in the Treatment of Parkinson's Disease, by Olanow, Agid, and Mizuno.